When was Adimab founded?

Adimab was founded in 2007 and raised its 1st funding round within a year of its incorporation.

How many employees does Adimab have?

As of Aug 31, 2026, the latest employee count at Adimab is 136.

Is Adimab a funded company?

Adimab is a funded company, having raised a total of $35.4M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 20, 2007.

When was the latest funding round of Adimab?

Adimab's latest funding was a $***** Series F round on Apr 02, 2012, with participation from 0 investor.

Where does Adimab rank among its competitors?

Adimab ranks 2nd amongst 875 active competitors, of which 60 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Helogen, which secured $7.1M in Sep, 2026.

Who are the top competitors of Adimab?

Adimab's top competitors include Alloy Therapeutics, Simulations Plus and Manifold Bio. Among them, Helogen secured the most recent funding round in September, 2026.

Adimab - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of yeast based discovery platforms for therapeutic protein engineering. This technology enables the discovery and optimization of fully human antibodies and multispecific formats. The process incorporates synthetic and immune libraries to facilitate antigen acquisition, high-throughput sorting, and hit characterization. Engineered candidates undergo assessment for binding, stability, and expression to ensure clinical developability. Services include platform transfer and support for generating therapeutic leads.

Website: adimab.com
Email ID: *****@adimab.com
Phone Number: +1 **********

Key Metrics

Founded Year

2007

Stage

Series F

Total Funding

$35.4M in 6 rounds

Latest Funding Round

Series F, Apr 02, 2012, $*****

Investors

Polaris Partners & 11 more

Ranked

2^nd among 875 active competitors

Employee Count

136 as on Aug 31, 2026

Investment & Acquisitions

Adagio

Similar Companies

Alloy Therapeutics & 896 more

View Adimab's full profile

Adimab is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Adimab, Llc CIN: 80-0669559 , United States, Active	Dec 14, 2010	-	121 (As on Dec 31, 2021)	-

Adimab has raised a total funding of $35.4M over 6 rounds. Its first funding round was on Jul 20, 2007. Adimab has 12 institutional investors.

Here is the list of recent funding rounds of Adimab:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 02, 2012	7836806	Series F	8896285	5800538	5983267	9025186
Nov 29, 2010	5583397	Series E	1642489	9833835	2360000	5413598
Oct 06, 2009	8325540	Series D	7873351	1262881	Google Ventures	Orbimed & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Adimab's funding rounds and investors

The founders of Adimab is Tillman Gerngross.

Here are the details of Adimab's key team members:

Tillman Gerngross: Co-Founder of Adimab and founder of 1 other company.
Contact Info: 1 email address

View details of Adimab's Founder profiles and Board Members

Adimab's employee count trend

Adimab has 136 employees as of Aug 26. Here is Adimab's employee count trend over the years:

Uncover Adimab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adimab include Alloy Therapeutics, Simulations Plus and Manifold Bio. Here is the list of Top 10 competitors of Adimab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alloy Therapeutics 2017, Lexington (United States), Series E	Provider of drug discovery services	$157M	8VC, Mubadala & 11 others	69/100
2nd	Adimab 2007, Series F	Developer of yeast based discovery platforms for therapeutic protein engineering	$35.4M	Mithril, Premji Invest & 10 others	65/100
3rd	Simulations Plus 1996, Lancaster (United States), Acquired	Developer of modeling and simulation software and consulting services provider	-	FDA, NIH & 1 others	60/100
4th	Manifold Bio 2018, United States, Series A	Developer of tissue-targeted therapeutics using in vivo screening and AI design	$78.2M	Playground Global, Triatomic & 8 others	54/100
5th	CILcare 2014, Montpellier (France), Series A	Service to develop health products aiming to diagnose, prevent, delay the progression or treat hearing loss and tinnitus	$42.3M	Shionogi, Galia Gestion & 5 others	54/100
6th	Helogen 2024, Mountain View (United States), Seed	Provider of space-based biomanufacturing and drug discovery services	$7.1M	RRE Ventures, Blisce & 3 others	52/100
7th	Viva Biotech 2006, Shanghai (China), Public	Research services focused on drug discovery and development	-	Temasek, Spinnotec & 3 others	51/100
8th	Superluminal Medicines 2022, Boston (United States), Series B	Generative biological and chemical company focused on drug discovery	$223M	RA Capital Management, BVF Partners & 9 others	51/100
9th	ArcaScience 2018, Paris (France), Seed	Developer of AI models for patient-centric insights in drug development	$7M	The Moon Venture, Kima Ventures & 5 others	51/100
10th	Arctoris 2016, Abingdon (United Kingdom), Seed	Provider of automated wet lab biology research and data generation services	$3.93M	RT, TD Veen & 7 others	51/100